Table 3.

Postdiagnosis vitamin supplement use in association with total mortality and breast cancer recurrence among women who received chemotherapy, SBCSS (N = 4,497)

Total mortalityBreast cancer recurrence
Vitamin useCohortNo. of eventsHRa (95% CI)PNo. of eventsHRa (95% CI)P
Never postdiagnosis2,8552701.00 (referent)3311.00 (referent)
Postdiagnosis use
 Any type1,6421350.89 (0.72–1.09)0.261700.87 (0.72–1.06)0.17
 Any antioxidantb1,267970.82 (0.64–1.04)0.091250.81 (0.66–1.00)0.05
Used during chemotherapy
 Any type1,3391120.91 (0.72–1.14)0.401460.93 (0.76–1.13)0.44
 Any antioxidantb998740.81 (0.62–1.05)0.111010.84 (0.67–1.06)0.13
Did not use during chemotherapy
 Any type303230.79 (0.52–1.22)0.29240.66 (0.43–1.00)0.05
 Any antioxidantb269230.85 (0.55–1.31)0.46240.71 (0.47–1.08)0.11
  • aHRs are adjusted for ER/PR status, TNM stage, radiotherapy, tamoxifen use, education, income, BMI, regular tea consumption, regular exercise participation (MET-hours per week), daily cruciferous vegetable intake, daily soy protein intake, and other vitamin variables in the table. Adjusted HRs and their corresponding 95% CIs were derived from Cox proportional hazards regression models, using age as the time scale.

  • bIncludes women who used vitamin C, vitamin E, and/or multivitamins.